Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

15 Dec 2016 16:31

RNS Number : 0050S
Midatech Pharma PLC
15 December 2016
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Midatech Pharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

Legal & General Assurance Society Limited (LGAS & LGPL)

 

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

14 December 2016

6. Date on which issuer notified:

15 December 2016

7. Threshold(s) that is/are crossed orreached:

 

 

 

LGIM (Above 10%) UTM (Above 5%)

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.00005

LGIM

 

 4,540,518.00

LGIM

 

 5,040,518

LGIM

 

 5,040,518

LGIM

 

10.35%

 

UTM

 

First Notification under DTR sourcebook

 

 

UTM

 

 

2,568,500

 

UTM

 

 

2,568,500

 

 

UTM

 

 

5.27%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 5,040,518

LGIM

 

10.35%

 

 2,568,500

UTM

 

5.27%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 5,040,518 -10.35% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 5,040,518 - 10.35% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 5,040,518 - 10.35% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 2,568,500 - 5.27% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) (PMC)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC) (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  48,699,456

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLTABFTMBTBBPF
Date   Source Headline
20th Dec 20177:00 amRNSMidatech initiates Gelclair Phase IV trial
22nd Nov 20177:00 amRNSMidatech receives manufacturing certification
7th Nov 20179:35 amRNSIssue of Equity for Midatech Share Incentive Plan
19th Oct 201710:52 amRNSHolding(s) in Company
19th Oct 20179:44 amRNSHoldings in Company
16th Oct 201712:44 pmRNSResult of General Meeting
28th Sep 20172:35 pmRNSResult of Placing to raise £6m & PDMR Shareholding
28th Sep 20177:01 amRNSInterim Results 2017
28th Sep 20177:00 amRNSProposed Placing and Open Offer
21st Sep 20179:00 amRNSHolding(s) in Company
7th Sep 20177:00 amRNSNotice of interim results
4th Sep 20177:00 amRNSMidatech submits MTD201 CTA filing
25th Aug 20171:59 pmRNSHolding(s) in Company
26th Jul 20177:00 amRNSCompletion of pre-clinical liver cancer programme
18th Jul 20177:00 amRNSTrading Update and Notice of Results
13th Jun 20177:00 amRNSSite visit for investors and analysts
7th Jun 20177:00 amRNSMidatech signs global agreement for panobinostat
22nd May 20177:00 amRNSProgress update on brain cancer therapies
19th May 20173:12 pmRNSIssue of Equity for Midatech Share Incentive Plan
3rd May 20172:30 pmRNSResult of AGM
4th Apr 20177:02 amRNSFinancial results for year ended 31 December 2016
14th Mar 20177:00 amRNSNotice of Results
10th Mar 20177:00 amRNSMidatech Announces Initial Scale-Up of Facility
27th Feb 20177:00 amRNSMidatech enters into Loan Agreement with SVB
20th Jan 201711:05 amRNSSecond Price Monitoring Extn
20th Jan 201711:00 amRNSPrice Monitoring Extension
20th Jan 20177:00 amRNSTrading Update
20th Dec 201612:56 pmRNSDirector/PDMR Shareholding
15th Dec 20164:31 pmRNSHolding(s) in Company
22nd Nov 20167:00 amRNSMidatech receives upfront on Emergex vaccine deal
15th Nov 20167:00 amRNSMidatech selects MTR104 for liver cancer treatment
2nd Nov 201612:57 pmRNSHolding(s) in Company
2nd Nov 20169:51 amRNSHolding(s) in Company
28th Oct 201611:12 amRNSResult of GM, Open Offer & Issue of Equity
11th Oct 20162:59 pmRNSResults of Placing to raise £16.0 million
11th Oct 201611:18 amRNSProposed Placing and Open Offer
30th Sep 20167:00 amRNSFirst in Human Immunotherapy Study Start
21st Sep 20167:00 amRNSMidatech Pharma US Partnership with R-Pharm US
2nd Sep 20167:00 amRNSInterim Results
10th Aug 20167:00 amRNSTrading Update and Notice of Results
7th Jul 20168:15 amRNSMidatech receives grant funding
30th Jun 20161:11 pmRNSAnnual Report Posting
27th Jun 20167:00 amRNSIssue of Equity and Director's Dealings
18th May 20167:00 amRNSMidatech Pharma announces clinical pipeline update
11th May 20165:28 pmRNSResult of AGM
11th May 20167:00 amRNSAGM Statement and Update on Trading
26th Apr 20167:00 amRNSMidatech announces positive Q-Octreotide data
21st Apr 20167:00 amRNSPositive data for OpsiSporin Uveitis programme
13th Apr 20167:00 amRNSFinancial results for the year ended 31 Dec 2015
11th Apr 20167:00 amRNSCommercial Launch of Zuplenz® (Ondansetron) in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.